Statement of Changes in Beneficial Ownership (4)
September 13 2017 - 06:21PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
STANZIONE DANIEL
|
2. Issuer Name
and
Ticker or Trading Symbol
QUEST DIAGNOSTICS INC
[
DGX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
500 PLAZA DRIVE
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
9/11/2017
|
(Street)
SECAUCUS, NJ 07094
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
9/11/2017
|
|
M
|
|
7316
|
A
|
$51.55
|
41991
|
D
|
|
Common Stock
|
9/11/2017
|
|
M
|
|
7319
|
A
|
$55.76
|
49310
|
D
|
|
Common Stock
|
9/11/2017
|
|
M
|
|
5592
|
A
|
$57.665
|
54902
|
D
|
|
Common Stock
|
9/11/2017
|
|
M
|
|
4268
|
A
|
$57.565
|
59170
|
D
|
|
Common Stock
|
9/11/2017
|
|
M
|
|
5221
|
A
|
$61.225
|
64391
|
D
|
|
Common Stock
|
9/11/2017
|
|
M
|
|
5592
|
A
|
$57.565
|
69983
|
D
|
|
Common Stock
|
9/11/2017
|
|
M
|
|
5592
|
A
|
$61.225
|
75575
|
D
|
|
Common Stock
|
9/11/2017
|
|
S
|
|
40900
|
D
|
$108.067
|
34675
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Options (Right to Buy)
|
$51.55
|
9/11/2017
|
|
M
(1)
|
|
|
7316
|
(2)
|
5/14/2019
|
Common Stock
|
7316.0
|
$51.55
|
0
|
D
|
|
Stock Options (Right to Buy)
|
$55.76
|
9/11/2017
|
|
M
(1)
|
|
|
7319
|
(3)
|
5/6/2020
|
Common Stock
|
7319.0
|
$55.76
|
0
|
D
|
|
Stock Options (Right to Buy)
|
$57.665
|
9/11/2017
|
|
M
(1)
|
|
|
5592
|
(4)
|
5/17/2021
|
Common Stock
|
5592.0
|
$57.665
|
0
|
D
|
|
Non-Qualifed Stock Option (right to buy)
|
$57.565
|
9/11/2017
|
|
M
(1)
|
|
|
5592
|
(5)
|
5/11/2022
|
Common Stock
|
5592.0
|
$57.565
|
0
|
D
|
|
Stock Options (Right to Buy)
|
$57.565
|
9/11/2017
|
|
M
(1)
|
|
|
4268
|
(5)
|
5/11/2022
|
Common Stock
|
4268.0
|
$57.565
|
0
|
D
|
|
Non-Qualifed Stock Option (right to buy)
|
$61.225
|
9/11/2017
|
|
M
(1)
|
|
|
5592
|
(6)
|
5/21/2023
|
Common Stock
|
5592.0
|
$61.225
|
0
|
D
|
|
Stock Options (Right to Buy)
|
$61.225
|
9/11/2017
|
|
M
(1)
|
|
|
5221
|
(6)
|
5/21/2023
|
Common Stock
|
5221.0
|
$61.225
|
0
|
D
|
|
Explanation of Responses:
|
(1)
|
This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017.
|
(2)
|
The options vested in three annual installments beginning with the first on May 14, 2010, the second on May 14, 2011 and the final on May 14, 2012.
|
(3)
|
The options vested in three annual installments beginning with the first on May 16, 2011, the second on May 6, 2012 and the final on May 6, 2013.
|
(4)
|
The options vested in three annual installments beginning with the first on May 17, 2012, the second on May 17, 2013 and the final on May 17, 2014.
|
(5)
|
The options vested in three annual installments beginning with the first on May 11, 2013, the second on May 11, 2014 and the final on May 11, 2015.
|
(6)
|
The options vested in three annual installments beginning with the first on May 21, 2014, the second on May 21, 2015 and the final on May 21, 2016.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
STANZIONE DANIEL
500 PLAZA DRIVE
SECAUCUS, NJ 07094
|
X
|
|
|
|
Signatures
|
/s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Daniel Stanzione
|
|
9/13/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Mar 2023 to Mar 2024